BioSpace News Archive

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced preliminary, unaudited financial highlights for the fourth quarter and full year ended December 31, 2023.

Janux Therapeutics, Inc. today announced the promotion of Dr. Tommy DiRaimondo to Chief Scientific Officer.

Cyclacel Pharmaceuticals, Inc. announced today that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) on January 4, 2024, indicating that the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules.

Alphatec Holdings, Inc. announced today preliminary revenue results for the fourth quarter and full-year ended December 31, 2023, and provided revenue guidance for full-year 2024.

Paragon 28, Inc. today announced a range of its preliminary unaudited net revenue for the fourth quarter and full year ended December 31, 2023.

Carlsmed announced today that new clinical data on its aprevo ® technology has been published in the Global Spine Journal.

Summit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare Conference

CoNextions Medical announced the CoNextions TR® Tendon Repair System has received an Innovative Technology contract from Vizient, Inc.

PTC Therapeutics, Inc. (NASDAQ: PTCT) will present an update on its commercial progress and R&D pipeline at the 42nd Annual J.P. Morgan Healthcare Conference today, Monday, January 8, at 10:30am EST/7:30am PST.

Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for degenerative eye diseases today announced the nomination to its Board of Directors of Dr. Theresa Heah.